Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SCTXBullishCorporate Developmentsnews

High materiality9/10

Scribe Therapeutics prices upsized IPO at $15 with Sanofi stake

Jul 23, 2026, 9:11 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Upsized, high-end IPO suggests strong demand; Sanofi anchor can support aftermarket trading, though dilution from new shares may temper gains once initial excitement fades.

AI summary

What happened, with direct paths to the underlying reporting

Scribe Therapeutics priced an upsized IPO at $15 per share, raising about $128.7 million in gross proceeds and offering a 30-day option for more shares. It also announced a concurrent private placement of 500,000 shares to Sanofi, signaling strategic backing. The Nasdaq listing on SCTX creates near-term price catalysts, with longer-term value tied to its CRISPR pipeline and collaborations.

Upsized IPO priced at $15; 8.58 million shares offered.
Gross proceeds expected about $128.7 million before expenses.
Concurrent private placement: Sanofi to buy 500,000 shares.
Trading on Nasdaq under SCTX to begin July 24, 2026; close July 27.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.